Bibliography
- Bork K, Hardt J, Wtzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 2012;130:692-7
- Bork K, Barnstedt SE, Koch P, et al. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000;356:213-17
- Bork K. Hereditary angioedema with normal C1 inhibitor. Immunol Allergy Clin North Am 2013;33:457-70
- Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009;124:801-8
- Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010;26:821-7. e814
- Cicardi M, Levy RJ, McNeil DL. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010;363:523-31
- Levy RJ, Lumry WR, McNeil DL, et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 2010;104:523-9
- Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010;363:532-41
- Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010;363:513-22
- Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 2008;100:153-61
- Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med 1972;287:452-4
- Zhang J, Krishnan R, Arnold CS, et al. Discovery of highly potent small molecule kallikrein inhibitors. Med Chem 2006;2:545-53
- Bantia S, Zhang J, Wilson R, et al. BCX4161, a small molecule orally bioavailable plasma kallikrein inhibitor for the treatment of hereditary angioedema [P756]. Proceedings of the Annual Meeting of the American Academy of Allergy, Asthma and Immunology; San Antonio, TX, USA; 2013
- BioCryst Initiates OPuS-1: a phase 2a clinical trial of BCX4161 in patients with hereditary angioedema. http://investor.shareholder.com/biocryst/releasedetail.cfm?ReleaseID=805452 [Accessed March 2014]
- Sexton D, Faucette R, Viswanathan M, et al. Discovery and characterization of a fully human monoclonal antibody inhibitor of plasma kallikrein for the treatment of plasma kallikrein-mediated edema. J Allergy Clin. Immunol 2013;131(Suppl):AB32-116
- Kenniston JA, Sexton DJ, Martik D, et al. Discovery and characterization of a highly specific antibody inhibitor of plasma kallikrein [P1067]. Annual Meeting of the American Society of Hematology; New Orleans, LA, USA; 2013
- Martinez-Saguer I, Cicardi M, Suffritti C, et al. Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study. Transfusion 2013. [Epub ahead of print]
- A study to evaluate the clinical efficacy and safety of subcutaneously administered C1-esterase inhibitor in the prevention of hereditary angioedema. Available from: http://clinicaltrials.gov/show/NCT01912456 [Accessed March 2014]
- Subcutaneous CINRYZE with recombinant human hyaluronidase for prevention of angioedema attacks. Available from: http://clinicaltrials.gov/ct2/show/NCT01756157?term=viropharma&rank=4 [Accessed March 2014]
- Larsson M, Rayzman V, Nolte MW, et al. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med 2014;6:222ra17
- R&D Briefing December 2013. Available from: http://www.csl.com.au/investors/briefings-presentations/operational-briefing.htm [Accessed March 2014]
- German Guidelines for Hereditary Angioedema due to C1-INH deficiency. Available from: www.angioedema.de/englisch/infos.htm [Accessed March 2014]